Gout FocusRheum

Understanding the role of NLRP3 inflammasome activation in gout flares points to potential of NLRP3 inflammasome inhibitors as new treatment option.

In a new-patient consultation for joint pain, you see a 75-year-old man with a history of dementia, stage 3a chronic kidney disease (CKD) and nephrolithiasis. He has a uric acid level of 7.5 mg/dL. His medication list includes 300 mg daily allopurinol. What is NOT an indication for allopurinol? CKD-FIX Elevated serum urate levels are…

Frailty & Prefrailty in Patients with RA TNF-α inhibitors associated with higher infection risk By Namrata Singh, MD, MSCI, Katherine D. Wysham, MD, James S. Andrews, MD, & Una E. Makris, MD Why was this study done? Frailty and prefrailty are more common and occur at a younger age in patients with rheumatoid arthritis (RA)…

At ACR Convergence 2023, experts addressed important topics in gout research, including treating and preventing gout flares, lowering urate levels and managing comorbidities, as well as racial inequities in gout treatment, disease burden and outcomes.

SAN DIEGO—Gout has sometimes been called the disease of kings, not only because of the fact that purine-rich foods were long affordable only to wealthier individuals, but also because the disease has been around since the monarchies that existed centuries ago. However, with groundbreaking research leading to a better understanding of gout, we can now…

SAN DIEGO—If patients with gout keep their serum urate (SU) levels very low with urate-lowering therapy (ULT), they have fewer flares, according to a research abstract presented at ACR Convergence 2023.

Canakinumab has received FDA approval for the treatment of patients with acute gout flares.

The 12-month results of the MIRROR study show pegloticase co-administered with methotrexate is beneficial for patients with uncontrolled gout.

Using data from the U.K.’s Health Improvement Network, a primary care database, Wei et al. examined whether urate-lowering therapy (ULT) in a treat-to-target approach for patients with gout reduces the risk of fracture.

In a dose-finding, clinical trial, Terkeltaub et al. examined the safety and efficacy of tigulixostat, a nonpurine xanthine oxidase inhibitor, for lowering the serum urate levels of patients with gout and hyperuricemia.